Prous Institute is launching a business model based on its drug discovery activities and proprietary technology to build partnerships and collaborations with industry, public health organizations and academia. The Institute is in close collaboration with a network of academic scientists to validate the predictions of the in silico models.
Food & Drug Administration (FDA), USA
The U.S. Food and Drug Administration and its Center for Drug Evaluation and Research (FDA/CDER) and Prous Institute for Biomedical Research (PIBR) will work jointly under a new 5-year research collaboration agreement (RCA) to develop hypothesis-based in silico predictive tools that are consistent with FDA’s Critical Path Initiative with drug safety in mind. These in silico predictive tools (i.e. computational models) are based on advanced computational analysis of drug molecular structures for carefully selected endpoints designed to facilitate regulatory and industry drug safety assessments by early identification of drug toxicity prior to significant human exposure.
Prous Institute Encourages Collaborative Research